A pioneering drug screening platform has been successfully developed by researchers, designed to identify compounds that directly address the fundamental…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
TWiV 1292: Clinical Update with Dr. Daniel Griffin Examines Public Health Decline, Vaccine Policy Shifts, and Resurgent Infectious Diseases
In a recent clinical update on the "This Week in Virology" (TWiV) podcast, Dr. Daniel Griffin and host Vincent Racaniello…
Read More
Rethinking evidence generation for ultra-rare diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…
Read More
LEO Pharma Acquires Gene Therapy Pioneer Replay to Revolutionize Treatment for Rare Genetic Dermatological Diseases
In a landmark move poised to redefine the landscape of dermatological therapeutics, LEO Pharma, a global leader in medical dermatology,…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read More
